

# Glyferon®

metformin hydrochloride

## FIRST LINE TREATMENT OF TYPE 2 DIABETES

ADULTS	
Starting dose	850 mg, two or three times a day
Your doctor may increase the dosage to a maximum of 3000 mg per day (as three divided doses) until your condition is under control.	
CHILDREN OF 10 YEARS AND OVER & ADOLESCENTS	
Starting dose	850 mg once daily
The maximum daily dose is 2000 mg per day taken as 2 or 3 divided doses.	
GLYFERON® has to be used by oral route with or after a meal. Swallow the tablet with one glass of water. The tablets may not be crushed or chewed.	

Type 2 diabetes is a progressive disease.  
Even if other molecules are eventually added,  
metformin remains the standard treatment for type 2 diabetes.

For information on our other brands, please  
visit [www.dafrapharma.com](http://www.dafrapharma.com) and create your  
personal account on our website.



SCAN

# Glyferon®

metformin hydrochloride



## FIRST LINE TREATMENT OF TYPE 2 DIABETES

Particularly for overweight patients.  
When diet and exercise alone are not enough to  
control the blood glucose levels.




### Setting the standard

[www.dafrapharma.com](http://www.dafrapharma.com)

# HYPERGLYCEMIA/ TYPE 2 DIABETES

## Potential complications



# Glyferon®

metformin hydrochloride



- Glyferon® 850 mg tablets
- Glyferon® 1g scored tablets
- Boxes of 30 film-coated tablets

## FIRST-LINE TREATMENT FOR TYPE 2 DIABETES

Particularly for overweight patients.  
When diet and exercise alone have failed to control blood glucose levels.

- first-line treatment of type 2 diabetes mellitus
- reduction in diabetes-related complications
- Dafra quality

For the SMPC, please scan this QR code.



SCAN

# Glyferon®

metformin hydrochloride

cardiovascular risk reduction in type 2 diabetic patients

UKPDS trial - Lancet 1998;352:837-853

- **reduction of fasting blood glucose 3.3 to 4.4 mmol/l (60 to 80 mg/dm)**
- **reduction of glycated haemoglobin (HbA&c): 1 to 2%**
- **32% reduction of diabetes-related end points**
- **42% reduction of diabetes-related deaths**
- **39% reduction of myocardial infections**
- **36% reduction of all-cause mortality**

Liver	Muscles	Adipose tissue
Glyferon® stimulates intracellular glycogen synthesis (glycogenesis) more glucose will be stocked as glycogen	Glyferon® increases the insulin sensitivity of muscle tissue	Glyferon® increases the insulin sensitivity of adipose tissue
inhibits glycogenolysis (conversion of glycogen to glucose) less glucose will be formed	improves glucose uptake (glycogenesis) more glucose will enter the tissues to be stocked/used	improves glucose uptake (glycogenesis) more glucose will enter the tissues to be stocked/used
inhibits gluconeogenesis (hepatic production of glucose) less glucose will be formed from free fatty acids	leads to a decrease in fatty acid oxidation	leads to a decrease in fatty acid oxidation

No risk of hypoglycemia

Glyferon® reduces the risk of myocardial infarction and mortality in overweight patients with type 2 diabetes. Apart from the effect on blood sugar, Glyferon® has a positive effect on lipids (total cholesterol - LDL and triglycerides).

